SAB Net Receivables from 2010 to 2026
| SABS Stock | USD 3.89 0.18 4.42% |
Net Receivables | First Reported 2020-09-30 | Previous Quarter 21.4 K | Current Value 560 K | Quarterly Volatility 7.9 M |
Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.2 M, Interest Income of 1.6 M or Depreciation And Amortization of 5.8 M, as well as many indicators such as Price To Sales Ratio of 34.17, Dividend Yield of 0.0 or PTB Ratio of 1.28. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.
SAB | Net Receivables | Build AI portfolio with SAB Stock |
The evolution of Net Receivables for SAB Biotherapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how SAB Biotherapeutics compares to historical norms and industry peers.
Latest SAB Biotherapeutics' Net Receivables Growth Pattern
Below is the plot of the Net Receivables of SAB Biotherapeutics over the last few years. It is SAB Biotherapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SAB Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
SAB Net Receivables Regression Statistics
| Arithmetic Mean | 3,675,031 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 130.50 | |
| Mean Deviation | 2,719,022 | |
| Median | 2,818,735 | |
| Standard Deviation | 4,795,910 | |
| Sample Variance | 23T | |
| Range | 20.6M | |
| R-Value | (0.03) | |
| Mean Square Error | 24.5T | |
| R-Squared | 0.0007 | |
| Significance | 0.92 | |
| Slope | (25,016) | |
| Total Sum of Squares | 368T |
SAB Net Receivables History
About SAB Biotherapeutics Financial Statements
SAB Biotherapeutics shareholders use historical fundamental indicators, such as Net Receivables, to determine how well the company is positioned to perform in the future. Although SAB Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in SAB Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on SAB Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 49.5 K | 47 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.